Tesamorelin

Compound identifiers & literature

Public database identifiers and a selection of peer-reviewed publications for Tesamorelin, provided so researchers can verify this compound independently. Each entry links to the primary source.

Selected literature

1. [1]
   Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P (2007). Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue Basic & Clinical Pharmacology & Toxicology.

   Preclinical pharmacology and repeat-dose toxicology package for TH9507 (tesamorelin), covering subcutaneous administration in pigs and subchronic toxicity studies of up to four months in Sprague-Dawley rats and in dogs, alongside in vitro peptide degradation in rat, dog and human plasma.

   rodent (rat), with additional dog and pig in vivo work and in vitro plasma degradation assaysPMID 17214611DOI
2. [2]
   Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV The New England Journal of Medicine.

   Randomized, double-blind, placebo-controlled trial in 412 adults with HIV and antiretroviral therapy-associated abdominal fat accumulation, comparing 2 mg/day subcutaneous tesamorelin with placebo over 26 weeks, with percent change from baseline in CT-measured visceral adipose tissue as the primary endpoint and lipid and glycemic parameters as secondary measures.

   human clinical trialPMID 18057338DOI
3. [3]
   Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data The Journal of Clinical Endocrinology and Metabolism.

   Pooled analysis of two phase 3 randomized placebo-controlled trials in 806 antiretroviral-treated adults with HIV and excess abdominal fat, randomized 2:1 in a 26-week primary phase (543 tesamorelin, 263 placebo) followed by a 26-week safety extension, reporting visceral adipose tissue, lipid, glucose and adverse-event data.

   human clinical trialPMID 20554713DOI
4. [4]
   Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial JAMA.

   Six-month double-blind randomized placebo-controlled trial in 50 antiretroviral-treated adults with HIV and abdominal fat accumulation (28 tesamorelin 2 mg/day, 22 placebo), measuring change in visceral adipose tissue by CT and hepatic fat by proton magnetic resonance spectroscopy, together with fasting and 2-hour glucose.

   human clinical trialPMID 25038357DOI
5. [5]
   Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial The Lancet HIV.

   Twelve-month randomized, double-blind, multicentre trial in 61 people with HIV and a hepatic fat fraction of at least 5% by proton magnetic resonance spectroscopy (30 tesamorelin, 30 placebo), assessing change in hepatic fat fraction along with paired liver biopsy histology and fibrosis staging.

   human clinical trialPMID 31611038DOI
6. [6]
   Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial Archives of Neurology.

   Twenty-week randomized, double-blind, placebo-controlled trial of 1 mg/day self-administered subcutaneous tesamorelin in 152 adults aged 55 to 87 years (66 with mild cognitive impairment, 86 cognitively healthy), followed by a 10-week washout, with performance on a battery of cognitive tests as the outcome measure.

   human clinical trialPMID 22869065DOI

These references are provided for scientific context only. They describe published research on this compound and are not evidence of safety or efficacy, not an endorsement of any use, and not medical advice. This product is supplied for laboratory research use only — not for human or animal consumption.